Record Quarterly and Full-Year Profitability
Adjusted EBITDA of $51.3M in Q4 2025 (highest quarter ever), representing ~20% growth YoY and an adjusted EBITDA margin of 21.2% (up 200 bps vs Q4 2024). Full-year sales of $913M with adjusted EBITDA of $186.2M and a 20.4% margin (company bests and above the 20% target).
Top-Line Growth and Revenue Mix
Consolidated Q4 revenue of $241.8M, up $18.4M (+8.3% YoY). Growth drivers included organic growth of 5.2%, foreign exchange tailwind of 2.5%, and acquisition contribution of 0.6% (Western Elevator).
Segment Momentum — Accessibility and Patient Care
Accessibility revenue growth of 7.7% in Q4 (North America +7.2%, Europe +9% with positive organic growth in Europe). Patient Care grew 10% in Q4, bringing full-year Patient Care growth to ~5%.
Improved Margins and Operating Results
Consolidated gross margin improved to 38.9% from 37.7% in 2024; operating income increased 36.6% YoY. Segment adjusted EBITDA margins: Accessibility 23.4%, Patient Care 19.4%.
Strong Cash Generation and Deleveraging
Cash flow from operations in Q4 of $35M; net debt reduced by $71M YoY, ending leverage ratio 1.03. Debt repayments totaled $45.2M in Q4 and $75.2M for 2025.
Savaria One Transformation Delivering Sustainable Gains
Savaria One delivered >160 initiatives in 2025 (roughly a dozen+ per month) with accelerating recurring savings; Q4 implementation of ~35 initiatives. Management describes improvements as structural and sustainable, with 100+ new initiatives planned for 2026.
M&A Firepower and Strategic Tuck-ins
Liquidity of ~$312M and stated capacity to invest ~$200M over the next few years while keeping leverage comfortably below 2x. Completed strategic tuck-ins (Western Elevator, Baxter Residential Elevator) to expand dealer footprint and product lines.
Disciplined CapEx and Continued R&D Investment
FY 2025 CapEx of $22M (2.4% of sales), Q4 CapEx $6.8M. 2026 CapEx guidance ~2.5%–3% of sales (one-off Greenville expansion), with expectation to return to ~2%–2.5% in 2027. R&D remains a focus (headcount ~62), with R&D and intangibles typically ~half of normal annual CapEx.